Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q antibodies and urinary erythrocytes have the best predictive power to dist ...

Early-life mutagenic exposure to colibactin-producing bacteria may be associated with the increased incidence of early-onset colorectal cancer.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

Machine learning has enabled spatiotemporal mapping of the four stages of the evolution of inflammatory bowel disease (IBD).

Among patients with acute LBP, use of nonpharmacologic therapy was associated with reduced risk for overdose-related hospitalizations.

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

Patients with vs without RA have a higher risk for avoidable hospitalizations for ambulatory care sensitive conditions, particularly heart failure and pulmonary edema.

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

Hospital-onset antimicrobial-resistant infections increased across US hospitals during and beyond the COVID-19 pandemic.